Peter G. Rose

18.2k citations

274 papers · 12.2k indexed · 2 hit papers · h-index 54

Impact in

Obstetrics and Gynecology top 0.02%
- Endometrial and Cervical Cancer Treatments
- Uterine Myomas and Treatments
Reproductive Medicine top 0.02%
- Ovarian cancer diagnosis and treatment
- Endometriosis Research and Treatment

Papers in

Reproductive Medicine 179
- Ovarian cancer diagnosis and treatment 171
- Endometriosis Research and Treatment 16
Obstetrics and Gynecology 124
- Endometrial and Cervical Cancer Treatments 119
- Uterine Myomas and Treatments 29

Co-authors: Daniel L. Clarke‐Pearson John A. Blessing J.T. Thigpen E. Blake Watkins Brian N. Bundy Mitchell Maiman Michael Rodriguez Chunqiao Tian
Journals: Gynecologic Oncology (103 papers)Journal of Clinical Oncology (30 papers)International Journal of Gynecological Cancer (19 papers)American Journal of Obstetrics and Gynecology (15 papers)Cancer (8 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Peter G. Rose

266 papers receiving 11.9k citations

Hit Papers

align trajectories log scale

Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study 2007 · 663 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2007 Journal of Clinical Oncology
1999 New England Journal of Medicine

Peers

Countries citing papers authored by Peter G. Rose

Since Specialization

Citations

This map shows the geographic impact of Peter G. Rose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter G. Rose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter G. Rose more than expected).

Fields of papers citing papers by Peter G. Rose

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter G. Rose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter G. Rose. The network helps show where Peter G. Rose may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Peter G. Rose, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter G. Rose Line = papers co-authored together Peter G. Rose links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial Clinical Cancer Research ·Jung‐Min Lee, Austin Miller, Peter G. Rose, Mariam AlHilli, N G Phillips, Veena S. John, Gudrun Poeschl, Koji Matsuo, Jean Siedel, David S. Miller, Won-Jun Cho, Daniel Luo, John K. Chan, Leslie Bradford, Christopher B. Morse, Christa Nagel, Kerry J. Rodabaugh, Elise C. Kohn, Kathleen N. Moore, Joyce F. Liu	2025	1
2	GOG-3084: A phase II trial of ADP-A2M4CD8 TCR-T cell therapy, alone or in combination with nivolumab, among patients with recurrent ovarian cancers Gynecologic Oncology ·Kathleen N. Moore, Ana Oaknin, Isabelle Ray‐Coquard, Robert L. Coleman, Thomas J. Herzog, David M. O’Malley, Stéphanie Lheureux, Peter G. Rose, Robert Morris, David Starks, Grainger S. Lanneau, Fernanda Musa, Michael J. Nathenson, 杨樟能, سیاوش نصیری, Siti Fathonah, Dennis Williams, Elliot Norry, Bradley Monk	2024	1
3	Association of Clinical Trial Participation With Improved Overall Survival for Recurrent, Platinum-Resistant Ovarian Cancer Obstetrical & Gynecological Survey ·Xiaohong Liu, A. A. Vertiy, Erika J. Lampert, Lilian Hancock Nance, Peter G. Rose, Robert Debernardo, Chad M. Michener, Roberto Vargas, Laura Chambers	2023	0
4	Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study American Journal of Obstetrics and Gynecology ·L. Phuong, Austin Miller, Amanda Black, Roni T. Falk, John F. Boggess, Katherine Tucker, Ashley Stuckey, Gustavo C. Rodriguez, Cheung Wong, Thomas Amatruda, Débora Salatino Palomares, Susan C. Modesitt, S. Diane Yamada, Kristin Bixel, Gretchen Glaser, Peter G. Rose, Mark H. Greene, Mark E. Sherman	2022	3
5	Long Term Survival of GOG 252 ‘Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/GOG Study’ (021) Gynecologic Oncology ·Joan L. Walker, Mohamed Mahmoud Mohamed, Kathleen N. Moore, Krishnansu S. Tewari, Premal H. Thaker, Paul DiSilvestro, Linda Van Le, Saketh R. Guntupalli, Heidi J. Gray, Peter G. Rose, David S. Alberts, Keiichi Fujiwara, Robert S. Mannel, Carol Aghajanian, Larry J. Copeland, Gini F. Fleming	2022	2
6	Oncologic effects of chemotherapy dose capping in overweight and obese ovarian cancer patients Gynecologic Oncology ·Michelle Kuznicki, Ágnes Vaskövi, PET GEOGRAFIA UFRGS, Peter G. Rose, Chad M. Michener	2021	2
7	Surgical lymph node assessment influences adjuvant therapy in clinically apparent stage I endometrioid endometrial carcinoma, meeting Mayo criteria for lymphadenectomy Journal of Surgical Oncology ·M. Robinson, Milena Radeva, Peter G. Rose	2021	3
8	Signaling within the epithelial ovarian cancer tumor microenvironment: the challenge of tumor heterogeneity Annals of Translational Medicine ·Max Horowitz, 菅浩二, Peter G. Rose, Ofer Reizes	2020	19
9	An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience Gynecologic Oncology ·Kate Oliver, William E. Brady, Michael J. Birrer, David M. Gershenson, Gini F. Fleming, Larry J. Copeland, Krishnansu S. Tewari, Peter A. Argenta, Robert S. Mannel, Angeles Alvarez Secord, Nancy Marivel Poma Soto, David G. Mutch, Frederick B. Stehman, Franco M. Muggia, Peter G. Rose, Deborah K. Armstrong, Michael A. Bookman, Robert A. Burger, John Farley	2017	62
10	Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy PMC ·Peter G. Rose, James Java, Charles W. Whitney, Frederick B. Stehman, Rachelle Lanciano, Gillian Thomas, Paul DiSilvestro	2015	3
11	Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study Gynecologic Oncology ·Haider Mahdi, Peter G. Rose, Lynn Rudich, Adnan Munkarah, Derek Isrow, Ren Shuzhi, Steven Waggoner, Rouba Ali‐Fehmi, Harry I. Subin, Dylan Tagrin, Pablo Noriega	2015	17
12	A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: A Gynecologic Oncology Group study Gynecologic Oncology ·Michael A. Gold, William E. Brady, Heather A. Lankes, Peter G. Rose, Joseph L. Kelley, Koen De Geest, Marta A. Crispens, Kimberly Resnick, Stephen B. Howell	2012	41
13	Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study Journal of Clinical Oncology ·Carol Aghajanian, Michael W. Sill, Kathleen M. Darcy, Benjamin E. Greer, D. Scott McMeekin, Peter G. Rose, Jacob Rotmensch, Mack N. Barnes, Parviz Hanjani, Kimberly K. Leslie	2011	214
14	Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial Gynecologic Oncology ·Martee L. Hensley, John A. Blessing, Robert S. Mannel, Peter G. Rose	2008	226
15	A Phase II Trial of Anastrozole in Advanced Recurrent or Persistent Endometrial Carcinoma: A Gynecologic Oncology Group Study Gynecologic Oncology ·Peter G. Rose, Virginia L. Brunetto, C.R. Singleton, Jeffrey G. Bell, Joan L. Walker, Roger B. Lee	2000	144
16	A Phase II Trial of Edatrexate in Previously Treated Squamous Cell Cervical Cancer American Journal of Clinical Oncology ·E. Randolph Broun, Dan Roche, Peter G. Rose, 賢治木村, John H. Malfetano, Jing Hong Min, Robert S. Mannel	1997	6
17	Phase II Evaluation of Altretamine for Advanced or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study Gynecologic Oncology ·Peter G. Rose, John A. Blessing, James C. Arseneau	1996	13
18	The cavitational ultrasonic surgical aspirator for cytoreduction in advanced ovarian cancer American Journal of Obstetrics and Gynecology ·Peter G. Rose	1992	32
19	Adjuvant therapy for Stage I uterine sarcoma American Journal of Obstetrics and Gynecology ·Peter G. Rose, John G. Boutselis, Larry Sachs	1987	26
20	Fine needle aspiration of ovarian masses. II. Correlative cytologic and histologic study of nonneoplastic cysts and noncelomic epithelial neoplasms. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Ibrahim Ramzy, Ayşe Merve Akkaya, Peter G. Rose	1979	34

About Peter G. Rose

Peter G. Rose is a scholar working on Reproductive Medicine, Obstetrics and Gynecology, Oncology, Surgery and Epidemiology, having authored 274 papers that have together received 12.2k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (171 papers), Endometrial and Cervical Cancer Treatments (119 papers), Intraperitoneal and Appendiceal Malignancies (53 papers), Cervical Cancer and HPV Research (34 papers), Uterine Myomas and Treatments (29 papers), Sarcoma Diagnosis and Treatment (20 papers), Colorectal and Anal Carcinomas (17 papers) and Endometriosis Research and Treatment (16 papers). The work is most often cited by research in Obstetrics and Gynecology (6.5k citations), Reproductive Medicine (5.8k citations), Oncology (3.2k citations), Surgery (4.1k citations) and Pulmonary and Respiratory Medicine (1.9k citations). Peter G. Rose has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Daniel L. Clarke‐Pearson, John A. Blessing, J.T. Thigpen, E. Blake Watkins, Brian N. Bundy, Mitchell Maiman, Michael Rodriguez, Chunqiao Tian, Amanda N. Fader and William P. McGuire. Their work appears in journals such as Gynecologic Oncology, Journal of Clinical Oncology, International Journal of Gynecological Cancer, American Journal of Obstetrics and Gynecology and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact